Showing results (231-240 of 297) with videos related to
Sort By:
Pageof 30
Journal of Cancer|September 20, 2021
Programmed Cell Death Protein 1/Programmed Cell Death Ligand-1 Axis activates Intracellular ERK Signaling in Tumor Cells to Mediate Poor Prognosis in T-cell LymphomaYang Li, Yue Fei, Lu Liu, et al.Aging|September 11, 2021
Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTKXianhuo Wang, Yue Fei, Xia Liu, et al.Frontiers in Oncology|May 28, 2020
Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 TrialJianhui Ma, Yan Song, Jianzhong Shou, et al.Signal Transduction and Targeted Therapy|December 1, 2025
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinibYuankai Shi, Dongqing Lv, Weineng Feng, et al.Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 27, 2025
CK2B Induces CD8+ T-Cell Exhaustion through HDAC8-Mediated Epigenetic Reprogramming to Limit the Efficacy of Anti-PD-1 Therapy in Non-Small-Cell Lung CancerShaochuan Liu, Shiya Ma, Gen Liu, et al.Oncotarget|June 11, 2016
Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patientsLin Zhang, Jian Wang, Feng Wei, et al.Journal of Immunology (Baltimore, Md. : 1950)|January 7, 2014
Activation of the epidermal growth factor receptor in macrophages regulates cytokine production and experimental colitisNing Lu, Lihong Wang, Hailong Cao, et al.Oncotarget|August 17, 2016
IL-2 augments the therapeutic efficacy of adoptively transferred B cells which directly kill tumor cells via the CXCR4/CXCL12 and perforin pathwaysYang Xia, Huimin Tao, Yangyang Hu, et al.Lung Cancer (Amsterdam, Netherlands)|March 6, 2022
A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitorsLin Lin, Hongming Pan, Xingya Li, et al.Frontiers in Immunology|May 10, 2017
Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem CellsLiang Liu, Lin Zhang, Lin Yang, et al.Pageof 30